{"DataElement":{"publicId":"2772158","version":"1","preferredName":"Disease Myelodysplastic Syndrome Hematology Response Type","preferredDefinition":"the type of hematologic improvement related to treatment of myelodysplastic syndrome, abnormal bone marrow cells that may lead to myelogenous leukemia, as an abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.","longName":"DZ_MDS_HEM_RESP_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2772156","version":"1","preferredName":"Disease Myelodysplastic Syndrome Hematology Response","preferredDefinition":"information related to the hematologic improvement related to treatment of myelodysplastic syndrome, abnormal bone marrow cells that may lead to myelogenous leukemia, as an abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.","longName":"DZ_MDS_HEM_RESP","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2772154","version":"1","preferredName":"MDS Hematology Response","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003:Hematology; the branch of medicine that deals with the blood and blood-forming organs and the diseases thereof.:In medicine, an improvement related to treatment.","longName":"C3247:C16673:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hematology","conceptCode":"C16673","definition":"The branch of medicine that deals with the blood and blood-forming organs and the diseases thereof.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"544615E2-5147-64AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"ONEDATA","dateModified":"2008-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008571","version":"1","preferredName":"Chronic or Associated Diseases and Exposures","preferredDefinition":"chronic diseases, as well as diseases and exposures associated with cancer.","longName":"CHR_O_ASS_DZ_AND_EXP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9B9249B-AB81-2F8D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-03-25","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-03-25","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"544615E2-5158-64AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2772157","version":"1","preferredName":"Myelodysplastic Syndrome Hematology Response Type","preferredDefinition":"the type of hematologic response for Myelodysplastic Syndrome.","longName":"MDS_HEM_RESP_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Relaspe MER","valueDescription":"Relapse major erythroid response","ValueMeaning":{"publicId":"2772159","version":"1","preferredName":"Relapse major erythroid response","longName":"2772159","preferredDefinition":"Relapse from transfusion independence in\r\ntransfusion-dependent patients or a rise in hemoglobin >2 g/dL in transfusion-independent\r\npatients with anemia for a minimum of eight consecutive weeks.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5446275C-CC91-3712-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54464653-5895-484D-E044-0003BA3F9857","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"ONEDATA","dateModified":"2008-08-12","deletedIndicator":"No"},{"value":"Major erythroid response","valueDescription":"Major erythroid response","ValueMeaning":{"publicId":"2772160","version":"1","preferredName":"Major erythroid response","longName":"2772160","preferredDefinition":"Transfusion independence in\r\ntransfusion-dependent patients or a rise in hemoglobin >2 g/dL in transfusion-independent\r\npatients with anemia for a minimum of eight consecutive weeks.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54464653-587E-484D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54464653-58A7-484D-E044-0003BA3F9857","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"ONEDATA","dateModified":"2008-08-12","deletedIndicator":"No"},{"value":"Minor erythroid response","valueDescription":"Minor erythroid response","ValueMeaning":{"publicId":"2772161","version":"1","preferredName":"Minor erythroid response","longName":"2772161","preferredDefinition":"The mean hemoglobin is\r\nsustained 1.0 to 2.0 g/dL above the baseline value for a minimum of 8 weeks; or a 50% or greater decrease in 8-week RBC transfusion requirements compared to baseline.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5444DD15-4D81-484F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54464653-58B9-484D-E044-0003BA3F9857","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"ONEDATA","dateModified":"2008-08-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"544615E2-516A-64AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811962","version":"1","longName":"Response","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"If Hematologic improvement","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5446275C-CC7F-3712-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"ALAIS","dateModified":"2009-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}